Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer (MER-HPV)
Recruiting
Observational Study
Oropharynx Squamous Cell Carcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 150 (estimated)
- Sponsor
- Region Skane · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to determine the value of circulating tumour HPV DNA (human papilloma virus DNA found in the blood) at diagnosis, during treatment, and in the follow-up of patients diagnosed and treated for throat cancer caused by HPV.
The main question to answer is if the presence of HPV DNA in the blood one month after the treatment is useful in detecting remaining tumour or …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Only patients with an HPV-positive primary tumour will eventually be eligible for inclusion.
Non-detectable ctHPVDNA at diagnosis will not be a reason for exclusion.
2. Age \>18 years.
3. Able to give informed consent.
4. The patient will be treated with curative intent.
…
Contacts